S1PR4
Sphingosine 1-phosphate receptor 4
As of the edition of 20 October 2026, S1PR4 (sphingosine 1-phosphate receptor 4, UniProt O95977) has 3 drugs tested at it and 6 companies on the list, 0 on route A and 2 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- O95977
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 1
- Disease areas
- Nervous system; Immune system; Heart and blood vessels; Digestive system; Skin and connective tissue; Cancer; Lungs and airways; Nutrition and metabolism
- Registered trials of its drugs
- 99
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Active | 2 |
| Total | 3 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Fingolimod | Marketed | Phase 4 | none listed |
| Amiselimod | Active | Phase 2 | none listed |
| NXC736 | Active | Phase 2 | none listed |
3 of 3 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route B | 2 |
| Engaged | 3 |
| Undetermined | 1 |
| Total on the list | 6 |
| Company | Route |
|---|---|
| Novartis | Route B |
| Mitsubishi Tanabe Pharma | Route B |
The other 4 companies at S1PR4
In the product6 companies in all; 4 are not named here, and no score is.
See the 6 companies at S1PR4, ranked, with the facts behind eachRequest access. Nothing is shown until you do.